Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine
AUTHORS
Kim, et al
Programs
OPN-51107
https://doi.org/10.1016/j.leukres.2022.106884
Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft- Versus-Host Disease
AUTHORS
Snyder, et al
Programs
OPN-2853 , OPN-51107
https://doi.org/10.3389/fonc.2021.760789
Phase 1b/2a Study of PLX2853, a Small Molecule BET Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma
AUTHORS
Gordon, et al
Programs
OPN-2853
Download PDF
A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
AUTHORS
Lee, et al
Programs
OPN-51107
https://doi.org/10.3324/haematol.2020.247346
Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
AUTHORS
Mims, et al
Programs
OPN-2853
Download PDF
BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression
AUTHORS
Cummin, et al
Programs
OPN-2853 , OPN-51107
https://doi.org/10.1182/bloodadvances.2020002231
Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma
AUTHORS
Tiago, et al
Programs
OPN-51107
https://doi.org/10.1038/s41416-019-0724-y
Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
AUTHORS
Pemmaraju, et al
Programs
OPN-2853
Download PDF
PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma
AUTHORS
Erkes, et al
Programs
OPN-51107
https://doi.org/10.1111/pcmr.12845
Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer
AUTHORS
Zhu, et al
Programs
OPN-51107
https://doi.org/10.1530/ERC-19-0107